Neurocrine Biosciences, Inc. (BVMF:N1BI34)

Market Cap	68.18B +3.2%
Revenue (ttm)	15.76B +21.4%
Net Income	2.64B +40.2%
EPS	25.72 +41.9%
Shares Out	n/a
PE Ratio	25.86
Forward PE	16.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108
Average Volume	174
Open	33.25
Previous Close	33.93
Day's Range	33.25 - 33.81
52-Week Range	25.64 - 44.18
Beta	0.36
RSI	42.15
Earnings Date	May 1, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 2,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: N1BI34

Financial Performance

In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.

Financial numbers in USD